Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
Tajeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8.
Ohnishi T, Horichi N, Adachi M, et al. Infection control in a teaching hospital without a tuberculosis ward. J Jpn Respir Soc. 2005;43(6):340–6.
The Prophylaxis Committee of the Japanese Society for Tuberculosis. Infection control in health care workers. Kekkaku. 2010;85(5):477–81.
Mori T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problem with these assays. J Infect Chemother. 2009;15:143–55.
Nakazono T, Tezuka N, Shimao T. Liver dysfunction during treatment of latent tuberculosis infection. Kekkaku. 2011;86(2):79–85.
Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, et al. Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol. 2010;20:18–23.
Chen D-Y, Shen G-H, Hsieh T-Y, Hsieh C-W, Lan J-L. Effectiveness of combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59(6):800–806